These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 22446485

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2013 Feb 15; 73(4):1340-51. PubMed ID: 23243017
    [Abstract] [Full Text] [Related]

  • 4. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.
    Mol Cancer Ther; 2012 May 15; 11(5):1122-32. PubMed ID: 22411899
    [Abstract] [Full Text] [Related]

  • 5. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR, Almenara JA, Coe S, Grant S.
    Cancer Res; 2007 Oct 01; 67(19):9490-500. PubMed ID: 17909059
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
    Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M.
    Cancer Res; 2008 May 01; 68(9):3413-20. PubMed ID: 18451169
    [Abstract] [Full Text] [Related]

  • 7. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
    Nguyen M, Cencic R, Ertel F, Bernier C, Pelletier J, Roulston A, Silvius JR, Shore GC.
    BMC Cancer; 2015 Aug 01; 15():568. PubMed ID: 26231047
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
    Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P.
    Mol Pharmacol; 2009 Aug 01; 76(2):327-41. PubMed ID: 19483105
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
    Lian J, Ni Z, Dai X, Su C, Smith AR, Xu L, He F.
    Mol Cancer Ther; 2012 Feb 01; 11(2):416-26. PubMed ID: 22188816
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
    Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, McCubrey J, Cortes J, Andreeff M.
    Leukemia; 2008 Apr 01; 22(4):808-18. PubMed ID: 18200035
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S.
    Clin Cancer Res; 2014 Sep 15; 20(18):4849-60. PubMed ID: 25070836
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, Dent P.
    Cancer Biol Ther; 2010 Nov 01; 10(9):903-17. PubMed ID: 20855960
    [Abstract] [Full Text] [Related]

  • 17. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S, Okumura K, Sinicrope FA.
    Clin Cancer Res; 2009 Jan 01; 15(1):150-9. PubMed ID: 19118042
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.
    Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A.
    Cell Death Dis; 2013 May 16; 4(5):e628. PubMed ID: 23681223
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S.
    Br J Haematol; 2011 Apr 16; 153(2):222-35. PubMed ID: 21375523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.